Moderna

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

Retrieved on: 
Wednesday, December 2, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Medical research, Medicine, Health, Clinical trials, BNT162b2, BioNTech, Vaccines, Pfizer, Vaccine, COVID-19 vaccine, Moderna, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech

This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic.

Key Points: 
  • This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic.
  • Our aim is to bring a safe and effective vaccine upon approval to the people who need it.
  • In July 2020, Pfizer and BioNTech announced an agreement with the U.K. to supply 30 million doses of the BNT162b2 mRNA-based vaccine, once authorized for emergency use.
  • Now that the vaccine is authorized in the U.K., the companies will take immediate action to begin the delivery of vaccine doses.

Pfizer and Moderna both Reported their COVID-19 Vaccines are About 95% Effective, However the Astrazeneca Vaccine Costs Less to Make

Retrieved on: 
Tuesday, December 1, 2020
Health sciences, Health, Medical research, Virology, Clinical research, Design of experiments, Vaccines, Moderna, AstraZeneca, Vaccine, Pfizer, Clinical trial

AstraZeneca could conduct another global clinical trial to test the efficacy of its vaccine at a lower dosage.

Key Points: 
  • AstraZeneca could conduct another global clinical trial to test the efficacy of its vaccine at a lower dosage.
  • AstraZeneca reported that the administering of the half dose had been reviewed by independent safety monitors and the British medicine regulator.
  • However, it could extend the length of time it takes for the vaccine to be approved in the US.
  • This month Pfizer and Moderna both reported their vaccines were about 95% effective.

Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?

Retrieved on: 
Tuesday, December 1, 2020
Stock market, Articles, Financial economics, Finance, Medical research, Moderna, Multimedia, Pharmaceutical industry in China, Stock

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.

Key Points: 
  • InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-t...

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on: 
Sunday, November 29, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Life sciences, Branches of biology, Medical research, Biology, Moderna, RNA, Messenger RNA, MHRA, Medicines and Healthcare products Regulatory Agency, COVID-19 vaccine

The UK government has now secured 7 million doses of mRNA-1273.

Key Points: 
  • The UK government has now secured 7 million doses of mRNA-1273.
  • For almost a decade, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines.
  • On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273.
  • This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna.

Moderna to Present at Upcoming Investor Conferences in December 2020

Retrieved on: 
Friday, November 27, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Genetics, Branches of biology, Life sciences, Biology, Medical research, RNA, Moderna, NASDAQ, Messenger RNA

Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 9:00 a.m.

Key Points: 
  • Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 9:00 a.m.
  • Nasdaq 43rd Virtual Investor Conference on Friday, December 4, 2020 at 12:00 p.m.
  • BMO 2020 Growth & ESG Conference on Wednesday, December 9, 2020 at 8:00 a.m.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on: 
Wednesday, November 25, 2020
Health, Infectious diseases, Clinical trials, General Health, Pharmaceutical, Biotechnology, Branches of biology, RNA, Life sciences, Biology, Medical research, RNA vaccine, Vaccine, Messenger RNA, Moderna, COVID-19 vaccine

Under the terms of the proposed agreement, the European Commission has the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses.

Key Points: 
  • Under the terms of the proposed agreement, the European Commission has the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses.
  • The agreement will be finalized following a brief review period by the European Union Member States.
  • This announcement follows the conclusion of advanced exploratory talks with the European Commission that began on August 24, 2020.
  • We appreciate the confidence the European Commission has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines.

Thinking about buying stock in HTG Molecular Diagnostics, Moderna, FuelCell Energy, BioNTech, or Blink Charging?

Retrieved on: 
Monday, November 23, 2020
Medical research, Financial markets, Articles, Stock market, Financial economics, BioNTech, Societates Europaeae, Multimedia, Moderna, Stock

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.

Key Points: 
  • InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-h...

European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

Retrieved on: 
Tuesday, November 17, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Life sciences, Branches of biology, Medical research, Biotechnology, Vaccines, Moderna, Messenger RNA, European Medicines Agency, COVID-19 vaccine

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Companys vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.

Key Points: 
  • Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Companys vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.
  • The start of the rolling review process marks an important next step as we continue to advance mRNA-1273 in collaboration with European regulatory authorities, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We will continue our ongoing dialogue with the EMA as we seek to develop a safe and effective vaccine.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

Retrieved on: 
Tuesday, November 17, 2020
Health, FDA, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical research, Health sciences, Medicine, Health, Vaccines, Moderna, COVID-19 vaccine, Department of Health and Social Care, MHRA, Medicines and Healthcare products Regulatory Agency, the Phase 3 COVE Study, mRNA-1273

This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines.

Key Points: 
  • This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines.
  • We appreciate the collaboration with the UK Government as with many other governments and other key partners around the world, said Stphane Bancel, CEO of Moderna.
  • On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273.
  • This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna.

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

Retrieved on: 
Monday, November 16, 2020
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical research, Branches of biology, Life sciences, Medicine, Vaccines, COVID-19 vaccine, Moderna, Messenger RNA, Vaccine, RNA vaccine

Shipping & Long-term Storage: For shipping and longer-term storage, Moderna expects that mRNA-1273 will be maintained at -20C (-4F), equal to most home or medical freezer temperatures, for up to 6 months.

Key Points: 
  • Shipping & Long-term Storage: For shipping and longer-term storage, Moderna expects that mRNA-1273 will be maintained at -20C (-4F), equal to most home or medical freezer temperatures, for up to 6 months.
  • The stability at refrigerated conditions allows for storage at most pharmacies, hospitals, or physicians offices.
  • The mRNA-1273 COVID-19 vaccine candidate is Modernas tenth mRNA vaccine to enter the clinic.
  • mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.